Harm Reduction International. (2020) Making the investment case: cost-effectiveness evidence for harm reduction. London: Harm Reduction International.
| Preview | Title | Contact |
|---|---|---|
|
PDF (Making the investment case: Cost-effectiveness evidence for harm reduction)
- Published Version
261kB |
In an era of shrinking international funding to address HIV, hepatitis C (HCV) and tuberculosis (TB), and competing priorities for domestic investment in health programmes, there is growing emphasis on ensuring value for money, efficient allocation of resources, and cost-effectiveness.
Item Type
Report
Publication Type
Report
Drug Type
All substances
Intervention Type
Harm reduction
Date
2020
Pages
4 p.
Publisher
Harm Reduction International
Corporate Creators
Harm Reduction International
Place of Publication
London
EndNote
Accession Number
HRB (Electronic Only)
Subjects
G Health and disease > Disease by cause (Aetiology) > Communicable / infectious disease > HIV
G Health and disease > Disease by cause (Aetiology) > Communicable / infectious disease > Hepatitis C (HCV)
J Health care, prevention, harm reduction and treatment > Health related issues > Health information and education > Communicable / infectious disease control > Needle syringe distribution and exchange
MP-MR Policy, planning, economics, work and social services > Programme planning, implementation, and evaluation > Programme and budget analysis (cost benefit)
VA Geographic area > International
G Health and disease > Disease by cause (Aetiology) > Communicable / infectious disease > Hepatitis C (HCV)
J Health care, prevention, harm reduction and treatment > Health related issues > Health information and education > Communicable / infectious disease control > Needle syringe distribution and exchange
MP-MR Policy, planning, economics, work and social services > Programme planning, implementation, and evaluation > Programme and budget analysis (cost benefit)
VA Geographic area > International
Repository Staff Only: item control page